Oral rivaroxaban for pulmonary embolism [1]

New England Journal of Medicine

Volumn 366, Issue 26, 2012, Pages 2525-2527

  O'Donnell, Dearbhaile M ^a   O'Connell, Niamh M ^a   O'Donnell, James S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; CANCER PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; LUNG EMBOLISM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; CLINICAL DECISION MAKING; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG USE; HEART MUSCLE INJURY; HEART RIGHT VENTRICLE FAILURE; RISK FACTOR; SHOCK; FEMALE; MALE; NOTE;

ANTICOAGULANTS; FEMALE; HUMANS; MALE; MORPHOLINES; PULMONARY EMBOLISM; THIOPHENES;

EID: 84862844503     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1205516     Document Type: Letter

References (3)

1. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
2. Lee AYY, Levine MN, Baker RI, et al. Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53. (Pubitemid 36818784)
3. National Comprehensive Cancer Network. Clinical practice guidelines (http://www.nccn.org/professionals/physician-gls/ pdf/vte.pdf).